Results 261 to 270 of about 54,917 (299)
Some of the next articles are maybe not open access.
Nihon rinsho. Japanese journal of clinical medicine, 2016
SGLT2 is a glucose transporter which plays an important role for reabsorption of urinary glucose depending on the sodium concentration gradient. SGLT2 is mainly present in apical site of S1 segment of renal proximal tubule and accounts for approximately 90% of total urinary glucose reabsorption. SLC5a2, which codes SGLT2, is also known as the causative
Naoto, Kubota, Takashi, Kadowaki
openaire +1 more source
SGLT2 is a glucose transporter which plays an important role for reabsorption of urinary glucose depending on the sodium concentration gradient. SGLT2 is mainly present in apical site of S1 segment of renal proximal tubule and accounts for approximately 90% of total urinary glucose reabsorption. SLC5a2, which codes SGLT2, is also known as the causative
Naoto, Kubota, Takashi, Kadowaki
openaire +1 more source
Journal of the American College of Cardiology, 2021
Richard K. Cheng +5 more
openaire +2 more sources
Richard K. Cheng +5 more
openaire +2 more sources
SGLT2 Inhibitors and Mechanisms of Hypertension
Current Cardiology Reports, 2018We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension.Inhibition of SGLT2 in the renal proximal tubule results in increased urinary glucose excretion and modest improvements of hemoglobin A1C.
Alexandros, Briasoulis +2 more
openaire +2 more sources
Risk of DKA with SGLT2 inhibitors
Drug and Therapeutics Bulletin, 2021Abstract Overview of: Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis. Ann Intern Med 2020;173:417–25.
openaire +2 more sources
The Functions of SGLT2 and the Recent Advances in the Studies of SGLT2 Inhibitors
MEMBRANE, 2021Yusuke Nakatsu, Tomoichiro Asano
openaire +1 more source
An update on the safety of SGLT2 inhibitors
Expert Opinion on Drug Safety, 2019Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are recommended after metformin for a large spectrum of patients with type 2 diabetes, because of a favorable benefit/risk profile despite a variety of adverse events.This narrative review discusses the safety profile of SGLT2is: initial concerns (cardiovascular safety, acute renal failure ...
openaire +2 more sources
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Annual Review of Physiology, 2021Subodh Verma, Volker Vallon
exaly
UHCW audit on SGLT2 inhibitor (SGLT2-i) use
Endocrine Abstracts, 2017Maria Mytilinaiou +7 more
openaire +1 more source